Peregrine to Report Second Quarter Fiscal Year 2011 Financial Results After Market Close on December 9, 2010

Peregrine Announces Initiation of Phase I/II Investigator-Sponsored Trial in Liver Cancer

Peregrine's Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic Fever Infection Models

Peregrine Awarded $977,917 Grant Under IRS Section 48D for Qualifying Therapeutic Discovery Projects

Avid Bioservices to Present at IBC's Preclinical Scale Bioprocessing Conference November 1-3, 2010

Peregrine Appoints Chairman of the Board and Announces Results From Annual Meeting of Stockholders

Peregrine to Present Bavituximab Antiviral Data at 2010 Chemical and Biological Defense Science and Technology Conference

Peregrine Reports Promising Interim Survival Data From Phase II Cotara(R) Brain Cancer Study

Data From Peregrine's Phase II Cotara Brain Cancer Trial to Be Presented at 2010 Congress of Neurological Surgeons Annual Meeting

Peregrine and Affitech to Amend License Agreements to Expedite Development of Novel Fully Human Anti-VEGF Antibody AT001/R84